Oryzon Genomics registers revenue of EUR 15.6m in 2022, up 47.2% over 2021
Oryzon Genomics registra ingresos de EUR 15,6m en 2022, un 47,2% más respecto a 2021
Intel ID : 359876
Relevant Documents
| Press Release | 17 Feb 2023 | Oryzon_Genomics_Press_Release_2023.pdf | EN |
|
| Intel ID | 359876 | |
| Value | EUR 15,60m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Oryzon Genomics
(31 Dec 2022) |
Revenue: EUR 15,95m Net Debt: EUR 539,03m People: 44 |
|
| Date |
 |
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Secondary Subsectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.99 Other Biotechnology & Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.06.01 Colleges & Universities 15 Consumer Products & Services / 15.06 Education & Training Services |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.